132 related articles for article (PubMed ID: 32675262)
1. Implementing Office-Based Opioid Treatment Models in Primary Care.
Brooks EM; Tong S
J Am Board Fam Med; 2020; 33(4):512-520. PubMed ID: 32675262
[TBL] [Abstract][Full Text] [Related]
2. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
Korthuis PT; McCarty D; Weimer M; Bougatsos C; Blazina I; Zakher B; Grusing S; Devine B; Chou R
Ann Intern Med; 2017 Feb; 166(4):268-278. PubMed ID: 27919103
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
4. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
5. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
6. An overview on medication-assisted treatment (MAT) for opioid dependence.
Maiti T; Das S; Ramasamy A; Stanley Xavier A; Kumar Behera S; Selvarajan S
J Opioid Manag; 2020; 16(2):141-149. PubMed ID: 32329889
[TBL] [Abstract][Full Text] [Related]
7. Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue.
McElrath K; Joseph H
Subst Use Misuse; 2018 Jan; 53(2):177-180. PubMed ID: 29220615
[TBL] [Abstract][Full Text] [Related]
8. An Innovative Model for Implementing Office-Based Opioid Treatment in Community-Based Settings.
Brooks EM; Brasler P
J Health Care Poor Underserved; 2020; 31(3):1054-1060. PubMed ID: 33416680
[TBL] [Abstract][Full Text] [Related]
9. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
10. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
[TBL] [Abstract][Full Text] [Related]
11. Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment.
Mirer AG; Tiemstra JD; Hammes NE; Cloum HM; LaFavor KJ
J Am Board Fam Med; 2022; 35(1):206-208. PubMed ID: 35039431
[TBL] [Abstract][Full Text] [Related]
12. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
13. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of opioid use disorder in pregnancy.
Rodriguez CE; Klie KA
Semin Perinatol; 2019 Apr; 43(3):141-148. PubMed ID: 30755340
[TBL] [Abstract][Full Text] [Related]
15. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
16. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
[TBL] [Abstract][Full Text] [Related]
17. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
[TBL] [Abstract][Full Text] [Related]
18. Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders.
Jacobs AA; Cangiano M
Prim Care; 2018 Dec; 45(4):731-742. PubMed ID: 30401353
[TBL] [Abstract][Full Text] [Related]
19. Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.
Miele GM; Caton L; Freese TE; McGovern M; Darfler K; Antonini VP; Perez M; Rawson R
J Subst Abuse Treat; 2020 Jan; 108():20-25. PubMed ID: 31399272
[TBL] [Abstract][Full Text] [Related]
20. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
